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Abstract
Background:  Aromatase, the cytochrome P-450 enzyme (CYP19) responsible for estrogen
biosynthesis, is an important target for the treatment of estrogen-dependent breast cancer. In fact,
the use of synthetic aromatase inhibitors (AI), which induce suppression of estrogen synthesis, has
shown to be an effective alternative to the classical tamoxifen for the treatment of postmenopausal
patients with ER-positive breast cancer. New AIs obtained, in our laboratory, by modification of
the A and D-rings of the natural substrate of aromatase, compounds 3a and 4a, showed previously
to efficiently suppress aromatase activity in placental microsomes. In the present study we have
investigated the effects of these compounds on cell proliferation, cell cycle progression and
induction of cell death using the estrogen-dependent human breast cancer cell line stably
transfected with the aromatase gene, MCF-7 aro cells.
Results: The new steroids inhibit hormone-dependent proliferation of MCF-7aro cells in a time
and dose-dependent manner, causing cell cycle arrest in G0/G1 phase and inducing cell death with
features of apoptosis and autophagic cell death.
Conclusion: Our in vitro studies showed that the two steroidal AIs, 3a and 4a, are potent
inhibitors of breast cancer cell proliferation. Moreover, it was also shown that the antiproliferative
effects of these two steroids on MCF-7aro cells are mediated by disrupting cell cycle progression,
through cell cycle arrest in G0/G1 phase and induction of cell death, being the dominant mechanism
autophagic cell death. Our results are important for the elucidation of the cellular effects of
steroidal AIs on breast cancer.
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Background
A large proportion of breast cancer patients are postmen-
opausal women with estrogen receptor-positive (ER)
tumors. After menopause, the main source of circulating
estrogens are extragonadal sites, such as liver, skin, muscle
and adipose tissue [1-3]. Recent advances in treatment
strategies, that inhibit the action of estrogen, have greatly
improved the range of effective therapeutic options for
breast cancer in postmenopausal women. In fact, hormo-
nal therapies have shown to be important tools in treating
ER-positive breast cancer and during the last two decades,
tamoxifen, which blocks the action of estrogen via the ER,
has been considered the gold standard therapeutic option
[4]. However, extensive evaluation of tamoxifen treat-
ment revealed adverse effects such as endometrial cancer
and blood clots. In addition, many ER-positive breast can-
cers do not respond to this therapeutic and resistance to
tamoxifen often develops during treatment, leading to
disease recurrence [5-7]. To circumvent these drawbacks
the use of third-generation aromatase inhibitors (AIs),
which prevent estrogen biosynthesis, is an effective alter-
native hormonal therapy and clinical guidelines are now
embracing AIs as appropriate adjuvant therapy for hor-
mone-sensitive early breast cancer [8,9]. These com-
pounds have demonstrated superior efficacy, reduced
incidence of endometrial cancer and blood clot formation
when compared to tamoxifen. Moreover, AIs have also
improved disease-free survival in a variety of adjuvant set-
tings for early breast cancer [9,10]. Steroidal and non-ster-
oidal AIs cause an effective suppression of estrogen
synthesis [11,12]. The former, such as exemestane and
formestane, compete with the endogenous ligands,
androstenedione and testosterone, for the active site of
the aromatase and are converted to intermediates that
bind irreversibly to the enzyme active site. Non-steroidal
AIs, like letrozole and anastrazole, bind reversibly to the
enzyme active site, competing with the substrate of aro-
matase. Despite the success of the third-generation steroi-
dal and nonsteroidal AIs, they also induce increased bone
loss, which may heighten the risk for osteoporotic frac-
tures and bone pain. In that way, it is essential to search
for other potent and specific molecules with lower side
effects. Moreover, it is of critical importance for the man-
agement of breast cancer treatment to understand the
pathways involved in the regression of breast tumors by
AIs.
For many years, research in the field of endocrine-medi-
ated breast cancer has focused on the proliferative effects
of estrogens. However, recent work has also demonstrated
a role for these steroidal hormones in the regulation of
apoptosis in neoplastic mammary tissue and in breast
cancer cell lines [13,14]. On the other hand, it has been
reported that estrogen stimulates the growth of breast can-
cer expressing functional ERs [15-17], by affecting cell
cycle machinery [18,19] and inducing expression of spe-
cific growth factors and their receptors [20,21]. It has been
reported that estradiol deprivation [22] or treatments with
selective estrogen receptor modulators (SERMs) [23-26],
antagonists of estrogen receptor [27] or aromatase inhibi-
tors [28] induce inhibition of cell proliferation and apop-
tosis in breast cancer cells. Treatment of breast cancer
using these endocrine strategies may induce cell death by
altered expression of Bcl-2 family proteins, altered expres-
sion of cell cycle associated proteins [13,27,28] or by
other mechanisms.
New synthetic AIs obtained by modifications in the A and
D- rings of the natural substrate of aromatase, androsten-
edione were developed and tested in our laboratory, for
aromatase inhibition in placental microsomes. Two of the
compounds synthesized, the 5α-androst-3-en-17-one
(3a) and the 3α ,4α-epoxy-5α-androstan-17-one (4a)
(Figure 1), have shown to be strong inhibitors of aro-
matase [29]. In the present study, we have investigated the
effects of these two steroidal aromatase inhibitors on cell
proliferation, cell cycle progression and induction of cell
death, using the estrogen-dependent human breast cancer
cell line stably transfected with the aromatase gene, MCF-
7aro.
Results
Morphological studies
In order to investigate the morphological changes
induced by inhibitors 3a and 4a in MCF-7aro cells, cells
were cultured with or without the compounds and exam-
ined by phase contrast microscopy (Figure 2). The
untreated control cells (medium with 1 nM T) did not
show any morphological alterations during the different
incubation periods. After 24 hr incubation with the differ-
ent concentrations of the two inhibitors no significant dif-
ferences in cell and nuclear morphology were observed.
However, after 3 and 6 days, MCF-7aro cells treated with
compounds  3a  and  4a  showed marked morphological
alterations. In treated MCF-7aro cells we could observe
non-adherent round cells, showing membrane blebbing,
Structures of the 3-deoxy steroid 3a and its 3,4-epoxide  derivative 4a Figure 1
Structures of the 3-deoxy steroid 3a and its 3,4-epox-
ide derivative 4a.
3a 4aBMC Cell Biology 2008, 9:41 http://www.biomedcentral.com/1471-2121/9/41
Page 3 of 14
(page number not for citation purposes)
as well as adherent cells characterized by the presence of
perinuclear vesicles in the cytoplasm (Figure 2). When
exposed to the higher doses of the compounds, an
increased number of these vesicles were observed in the
cells. Additionally, Wright and Hoechst 33258 staining
(Figure 3) confirmed the cellular changes upon treatment
with the compounds. Treatment of MCF-7aro cells with
higher concentrations of 3a  and  4a  (25 and 50 μM)
resulted in dramatic alterations in cellular morphology
with condensed marginalized chromatin and vacuoliza-
tion of the cytoplasm.
Cell viability and cell proliferation
A significant dose- and time-dependent reduction in cell
number was observed when cells were incubated with
compounds 3a and 4a. Cell viability was evaluated by
flow cytometry using 7AAD- fluorescence. 7AAD-ve cells
were considered as viable cells. Treatment of MCF-7aro
cells with compound 3a for 72 hr, resulted in a reduced
number of 7AAD-ve cells: 29.4 ± 7.1%, 43.6 ± 1.0% and
44.3 ± 0.4%, respectively for 1, 10 and 25 μM, whereas
compound 4a reduced cell viability in 13.1 ± 3.1%, 38.4
± 3.7% and 66.6 ± 1.2%, respectively for 1, 10 and 25 μM,
in comparison to the control (Figure 4). To address the
direct effect of aromatase inhibitors 3a and 4a on the pro-
liferation of MCF-7aro cells, thymidine incorporation
assays were performed. For this purpose, exponentially
growing cells were treated with different concentrations
(1–50 μM) of the inhibitors, 3a and 4a, for 1–6 days. As
shown in Figure 5, these compounds inhibited MCF-7aro
cell growth in a dose- and time-dependent manner. The
time-response profile obtained for both inhibitors
showed a biphasic effect in DNA synthesis of MCF-7aro
cells. At short exposure times, compounds 3a and 4a stim-
ulated DNA synthesis of MCF-7aro cells. In fact, after 24
hr incubation, compound 3a induced 66 ± 20%, 78 ± 7%
and 22 ± 13% and compound 4a induced 22 ± 14%, 41 ±
6% and 35 ± 17% increase in DNA synthesis, respectively
for 1, 10 and 25 μM, considering the control as 100%. For
24 hr incubation of MCF-7aro cells with 3a and 4a at 50
μM, a slight decrease in thymidine incorporation was
observed. After this period, when cells were treated for 3
and 6 days with these compounds, the stimulatory effect
was replaced by a decrease on DNA synthesis. Long-term
exposure of MCF-7aro to 3a and 4a at the concentration
range used resulted in an effective inhibitory effect on
DNA synthesis. For instance, after 6 days of incubation,
compound 3a resulted in 18 ± 8%, 37 ± 10%, 50 ± 2% and
80 ± 3% and compound 4a in 37 ± 5%, 52 ± 5%, 68 ± 3%
and 86.5 ± 2% decrease in thymidine incorporation
Morphological changes of MCF-7aro cells treated with compounds 3a and 4a Figure 2
Morphological changes of MCF-7aro cells treated with compounds 3a and 4a. (A) hormone depleted medium, (B) 
untreated cells, or treated for 72 hr with 3a (C-D) and 4a (E-F), respectively with 10 and 25 μM. Arrows indicate multiblebbing 
cells and arrowheads indicate perinuclear vesicles in the cytoplasm.BMC Cell Biology 2008, 9:41 http://www.biomedcentral.com/1471-2121/9/41
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respectively for 1, 10, 25 and 50 μM. So compound 4a
showed to be slightly more effective in inhibiting MCF-
7aro cell proliferation than 3a.
Cell cycle analysis
To investigate the mechanisms underlying the antiprolif-
erative effect of compounds 3a and 4a in MCF-7aro cells,
discrimination of cells in G0/G1 versus S and G2/M phases
of cell cycle was carried out by measuring DNA content by
flow cytometry. Cells were treated with different concen-
trations of these two compounds and stained, after 24 hr,
with PI. MCF-7aro cells deprived of hormones showed
91.3 ± 2.1% of cells in G0/G1 phase, whereas in testoster-
one-induced growth of MCF-7aro cells (control cells), the
percentage of cells arrested in G0/G1 phase was only 42.4
± 2.3%, which indicates that aromatase present in MCF-
7aro is converting testosterone into estradiol, inducing in
that way cell proliferation. The cell cycle profile of MCF-
7aro cells treated with 3a or 4a was similar (Figure 6).
Each treatment clearly increased the percentage of MCF-
7aro cells in G0/G1 phase and reduced the fraction of cells
in S and G2/M cell cycle phases (Figure 6 and Table 1). In
response to treatment with 3a, a dose-dependent accumu-
lation of cells in G0/G1 phase was observed: 52.4 ± 6.8%,
53.6 ± 2.2%, 65.9 ± 2.1% and 72.2 ± 1.5%, respectively
for 1, 10, 25 and 50 μM compared with 42.4 ± 2.3% in the
Effects of compounds 4a on cell morphology Figure 3
Effects of compounds 4a on cell morphology. Cultured MCF-7aro cells were examined in the absence (A, B) or in the 
presence of 25 μM of 4a (C, D) in a medium containing 1 nM T for 72 hr. Wright staining shows that cells treated with 4a have 
condensed and marginalized chromatin (arrowheads) and cytoplasm vacuolization (arrows) (C) in comparison to the control 
cells (A). Nuclear morphological changes in MCF-7aro cells were demonstrated by Hoechst 33258 staining under the fluores-
cence microscope. Untreated cells exhibited normal nuclear morphology and the presence of abundant mitotic figures (open 
arrows) (B). Treatment with 4a induced chromatin condensation (arrows) (D).
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control (Table 1A). Like steroid 3a, compound 4a pre-
sented a dose-dependent increase in the cell percentage in
G0/G1: 58.6 ± 18.0%, 43.6 ± 1.4%, 59.6 ± 2.2%, 78.2 ±
2.3%, respectively for 1, 10, 25 and 50 μM (Table 1B). The
same pattern of steroidal AIs effect on cell cycle progres-
sion were also observed after 3 days of treatment however
no statistically significant differences was found.
Analysis of cell death
As shown previously (Figure 2, 3), incubation of MCF-
7aro cells with compounds 3a and 4a caused alterations
in cell morphology, such as membrane blebbing, chroma-
tin condensation/marginalization and appearance of peri-
nuclear vesicles in the cytoplasm. In order to investigate
the type of cell death induced by these compounds, fea-
tures associated with apoptosis or autophagic cell death
were assessed. For apoptosis, plasma membrane changes
such as phosphatidylserine (PS) residues in the outer sur-
face of the plasma membrane were evaluated by annexin
V-PE apoptosis detection kit. Staining with annexin V-PE
was performed in association with a vital dye 7-amino-
acitomycin (7-AAD), to allow the identification of viable,
early apoptotic and late apoptotic or necrotic cells.
Untreated MCF-7aro cells presented 9.2% binding to
annexin V (Figure 7), whereas cells treated with 3a at 1 μM
and 10 μM showed 24.7% and 41.8%, respectively. Inhib-
itor  4a  induced an increased binding to annexin V of
14.05% and 32.53%, respectively for 1 μM and 10 μM in
comparison to the control (9.2%). Caspases-3/7 activity
was evaluated, but no changes were observed (data not
shown) for both compounds at different incubation peri-
ods (6–96 hr).
In order to clarify the nature of the cytoplasmic structures
observed in the treated cells (Figure 2 and 3), the auto-flu-
orescent substance MDC, a dye for autophagic vacuoles,
was used. In cells treated with compounds 3a or 4a (25
μM), MDC-labelled autophagic vacuoles appeared as dis-
tinct dot-like structures distributed in the cytoplasm or in
the perinuclear regions whereas in the untreated cells,
there was a homogeneous distribution of MDC (Figure 8).
After 3 days, ultrastructural analysis demonstrated that the
compounds induced an apoptotic-like nuclear morphol-
ogy characterized by a partially condensed chromatin
marginalized along the nuclear envelope (Figure 9). In
addition, the cells presented giant autophagosomes dis-
tributed throughout the cytoplasm containing cytoplas-
matic fragments and mitochondria.
Discussion
Estrogens promote cell proliferation in normal and trans-
formed mammary epithelial cells, activating hormone-
responsive genes involved in the regulation of cell cycle.
Studies have shown that anti-estrogenic treatment or
estrogen deprivation prevents MCF-7 cells to enter the S
and G2/M phase [13,28]. In addition to cell cycle progres-
sion, estrogens are known to protect cells against cell
death by apoptosis. Several studies both in vitro and in vivo
have reported that estrogen withdrawal [22] and treat-
ment with either tamoxifen [23-25], faslodex [27] and
some AIs [28] induce apoptosis of estrogen-dependent
breast cancer cells. Anti-hormonal treatments of breast
cancer are therefore central in regard to their potent inhib-
itory effects in hormone-induced cell growth.
This study explored the in vitro effects of compounds 3a
and 4a in MCF-7aro cell growth, cell cycle progression
and induction of cell death. In this system, MCF-7aro
breast cancer cell line expressed sufficient aromatase activ-
ity in order to stimulate cell growth via aromatization of
testosterone to estradiol. In fact, this androgen signifi-
cantly stimulated MCF-7aro cells growth at concentra-
tions as low as 1 nM, which is within the physiological
concentration range for this steroid hormone. In the
present work, we showed that compounds 3a  and  4a,
which have previously demonstrated to efficiently inhibit
aromatase in placental microsomes [29] and in different
cell lines [33], have also the ability to inhibit the prolifer-
ative action of testosterone in MCF-7aro cells in a dose-
and time-dependent manner. This indicates that aromati-
zation of the androgen with production of E2 was respon-
sible for the testosterone-mediated cell growth. However,
at 24 hr incubation, this effect was not observed. Indeed,
inhibitors 3a and 4a induced stimulation of DNA synthe-
sis, which might be due to estrogenic-like effects. A similar
pattern of cell proliferation has been described for other
compounds [34-37]. When assessing cell cycle it was
found an increase in G0/G1 and a decrease in S and G2/M
Effects of 3a and 4a on cell viability Figure 4
Effects of 3a and 4a on cell viability. MCF-7aro cells 
treated with 3a and 4a induced a decrease in 7AAD-ve cells, 
in comparison to control. Data are expressed as the percent-
age of 7AAD-ve cells and are representative of triplicate cul-
tures and three independent experiments.
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Effects of inhibitor 3a (A) and 4a (B) on rate of DNA synthesis Figure 5
Effects of inhibitor 3a (A) and 4a (B) on rate of DNA synthesis. MCF-7aro cells were cultured in steroid-free medium 
without phenol red for 3 days before plating. Triplicate wells were treated with the indicated concentrations of the compounds 
in medium containing 1 nM T. Cells cultured with testosterone represented maximum cell proliferation and were considered 
as control. 3a and 4a induced a decrease in cell proliferation, evaluated by the thymidine incorporation assay, in a time- and 
dose-dependent manner. Results are the mean ± SE of three independent experiments whereas cultures were performed in 
triplicate. Significant inhibition relative to the control level is denoted by * (P < 0.001), ** (P < 0.01) and θ (P < 0.05).
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Table 1: Effects of steroids 3a (A) and 4a (B) on cell cycle distribution of human breast cancer MCF-7aro cells.
A Control T T + 3a1 μM T + 3a10 μM T + 3a25 μM T + 3a50 μM
G0/G1 91.3 ± 2.1 42.4 ± 2.3 * 52.4 ± 6.8 φ 53.6 ± 2.2 φ 65.9 ± 2.1 φ 72.2 ± 1.5 φ
S 4.8 ± 1.2 48.4 ± 2.3 * 39.7 ± 5.5 φ 38.3 ± 6.5 φ 25.8 ± 3.3 φ 19.6 ± 4.2 φ
G2/M 5.0. ± 2.1 10.2 ± 2.4 9.94 ± 1.7 7.2 ± 4.6 7.4 ± 2.7 8.9 ± 2.6
B Control T T + 4a1 μM T + 4a10 μM T + 4a25 μM T + 4a50 μM
G0/G1 91.3 ± 2.2 42.4 ± 2.3 * 58.6 ± 18.0 43.6 ± 1.4 59.6 ± 2.2 φ 78.2 ± 2.3 φ
S 4.8 ± 1.2 48.4 ± 2.3 * 33.8 ± 17.3 43.4 ± 3.5 35.3 ± 0.1** 18.9 ± 1.8 φ
G2/M 5.0 ± 2.1 10.2 ± 2.4 10.7 ± 1.4 13.1 ± 1.9 4.1 ± 2.2 3.0 ± 0.1
Cells were treated with different concentrations of the compounds for 24 hr. Treated cells were harvested, fixed and their DNA content was 
evaluated by PI labelling followed by flow cytometry analysis. Data are presented as single cell events in G0–G1, S and the G2-M phases of the cell 
cycle. The data represents means and SE of triplicates and are representative of three independent experiments. Significant differences between the 
control (medium without hormones) and medium containing 1 nM T are indicated by * (P < 0.0001); medium containing 1 nM T vs medium 
containing different steroid concentrations are indicated as φ (P < 0.001), ** (P < 0.01) and θ(P < 0.05).
Effects of compounds 3a and 4a on cell cycle distribution Figure 6
Effects of compounds 3a and 4a on cell cycle distribution. MCF-7aro cells were treated with 3a and 4a at 1 and 25 μM 
for 24 hr and subjected to flow cytometric analysis after PI staining. Compounds 3a and 4a induced cell cycle arrest in G0/G1 
phase. Histograms were analysed with FlowJo Software (Tree Star, Inc). Data are representative of three independent experi-
ments performed in triplicate.
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Annexin V-PE labelling of MCF-7aro cells treated with 3a and 4a in comparison to control Figure 7
Annexin V-PE labelling of MCF-7aro cells treated with 3a and 4a in comparison to control. Cells were stained 
with annexin V-PE and 7-AAD and analysed by flow cytometry. Compounds 3a and 4a (gray filled histograms) induced an 
increase in annexin V binding in MCF-7aro cells, in comparison to 9.2% of the control (medium containing 1 nM T, open histo-
grams). Numbers in histograms are percent of annexin V-positive cells after treatment with the compounds. The histograms 
correspond to cells gated for negative 7-AAD staining. Data are representative of triplicate cultures and the figure is represent-
ative of three independent experiments.
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phases. We demonstrated that both aromatase inhibitors
induce growth arrest of MCF-7aro cells by blocking the
G1/S phase transition of cell cycle or a prolonged transit
time in G1, preventing cells to enter S phase, which subse-
quently led to a decrease in the percentage of cells in S and
G2/M phase. Moreover, thymidine incorporation results
together with the fraction of cells in S phase suggest that
cell proliferation may continue though with a reduction
in growth rate. Analysis of cell cycle suggests that the
mechanisms of action of both compounds are identical.
These results are in accordance to a previous study [28] in
which similar effects were induced by other AIs, like letro-
zole (Let), anastrozole (Ana), and 4-hydroxyandrostene-
dione (4-OH-A), in the cell cycle distribution of estrogen-
dependent breast cancer cells.
Visualization of autophagic vacuoles with MDC in MCF-7aro cells Figure 8
Visualization of autophagic vacuoles with MDC in MCF-7aro cells. MCF-7aro cells were incubated in the absence (A) 
or in the presence (B) of 25 μM of compound 4a in medium containing 1nM T. After 72 hr incubation with the compounds, 
cells were treated with MDC for 1 hr at 37°C, washed with PBS and analysed by fluorescence microscopy. The formation of 
autophagic vacuoles in MCF-7aro cells treated with compound 4a was indicated by punctuated MDC labelling in the cytoplasm.
A B
Ultrastructural features of cell death in control MCF-7aro cells (A) and after treatment with 25 μM compound 4a (B-C) after  72 hr incubation Figure 9
Ultrastructural features of cell death in control MCF-7aro cells (A) and after treatment with 25 μM compound 
4a (B-C) after 72 hr incubation. (A) The cytoplasm tipically shows multiple polyribosomes and numerous mitochondria. (B) 
The cytoplasm shows multiple autophagic vacuoles containing cytoplasmic fragments (arrows). The chromatin is irregularly 
condensed (arrowheads). (C) is ahigher magnification of (B).BMC Cell Biology 2008, 9:41 http://www.biomedcentral.com/1471-2121/9/41
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We believe that the reduction in cell number induced by
treatment of MCF-7aro cells with these inhibitors is due,
not only to the prevention of cell proliferation by cell
cycle arrest, but also to the induction of cell death. Thus,
it is important to understand the mechanisms associated
with cell death resulting from the treatment of ER-positive
cells with inhibitors of aromatase. Our results showed
that the treated cells presented morphological alterations
typical of cells undergoing apoptosis, such as condensa-
tion/marginalization of chromatin and membrane bleb-
bing, as well as vacuolization of the cytoplasm, a feature
of autophagy. Typical apoptotic bodies were not
observed. Previous studies revealed that MCF-7 cells are
responsive to apoptotic stimuli [38] and although DNA
fragmentation occurs [39], they lack pro-caspase-3
polypeptide [38]. Moreover, in previous published data
using MCF-7 [39,40] and MCF-7aro cells [28], activation
of caspase-3/7 was not observed for any of the treatments,
which is in accordance to our results. This study also
showed that compounds 3a  and 4a  induced increased
binding of annexin V on MCF-7aro cells after 72 hr of
treatment related with the phosphatidilserine exposure on
the cell surface, which is known to have a key role on the
clearance of apoptotic cells [41]. Nevertheless, Madden
and colleagues [42] have shown that phosphatidylserine
exposure, in addition to being a marker of apoptosis, can
also occur in cells dying by autophagic cell death. Moreo-
ver, electron microscopy revealed the presence of many
isolated autophagossomes engolfing cytoplasmic frac-
tions and organelles. It has been reported that although
features of various death pathways can be exhibited, only
the most effective one is usually evident. In fact,
autophagic cell death was induced in a promonocyte cell
line treated with arsenic trioxide [43] and TGF-β induced
both apotosis and autophagy in a mammary bovine cell
line [43,44]. Electron microscopy results with 3a and 4a-
treated MCF-7aro cells reinforce the origin of MDC-
stained vesicles, showing the presence of multiple
autophagosomes dispersed throughout the cytosol. It
seems that different pathways of programmed cell death
can be induced by these anti-aromatase treatments, ie.
apoptosis and autophagic cell death, suggesting mutual
interactions between these two types of cell death, how-
ever the molecular switch is not defined. Several studies
pointed out that there is a crosstalk between apoptosis
and autophagic cell death. Execution of apoptosis can be
preceded by and may even depend on autophagy [45-47]
or autophagy may rather antagonize or delay apoptosis
and its inhibition may increase the sensitivity for the cells
to apoptotic signals [48]. Motyl and colleagues have also
shown that apoptosis might be accompanied by increased
autophagy as a cytoprotective process, but in advanced
stages might result in a particular type of programmed cell
death. The threshold that separates these two processes is
not clear and might depend on the extension of degrada-
tion of cellular components [44]. Some authors have pre-
viously shown that some AIs [28] induce cell death of
breast cancer cell lines by apoptosis. However, it has also
been reported that various anticancer therapies, including
tamoxifen and other anti-estrogenic agents, induced
autophagic cell death in breast cancer MCF-7 cells [49-52]
and in FM3A breast cancer cells [53], and crotoxin can
also induced this type of programmed cell death in MCF-
7 cells [54].
Conclusion
Our in vitro studies showed that the two steroidal AIs, 3a
and 4a, are potent inhibitors of breast cancer cell prolifer-
ation. Moreover, it was also shown that the antiprolifera-
tive effects of these two steroids on MCF-7aro cells are
mediated by disrupting cell cycle progression, through cell
cycle arrest in G0/G1 phase and induction of cell death. We
believe that both autophagic cell death and/or caspase-3
independent apoptosis may participate in MCF-7aro cell
death induced by 3a and 4a, being the dominant mecha-
nism autophagic cell death. The precise mechanisms
underlying the different roles of autophagic cell death and
the signalling pathways activated upon treatment of
breast cancer cells with these steroidal AIs remain to be
studied. In this way, it is important to understand the
molecular components and signalling pathways of cell
death machinery of cancer cells to help in the establish-
ment of appropriate therapeutics, in order to provide new
insights into the treatment of tumours with AIs.
Methods
Materials
Eagles's minimum essential medium (MEM), fetal bovine
serum (FBS), L-glutamine, antibiotic-antimycotic 100×
(10000 units/ml penicillin G sodium, 10000 mg/ml
streptomycin sulphate and 25 mg/ml amphotericin B),
Geneticin (G418) and trypsin were supplied by Gibco
Invitrogen Co. (Paisley, Scotland, UK). Trypan blue, testo-
sterone (T), ethylenediaminetetracetic acid (EDTA),
dimethylsulfoxide (DMSO), sodium pyruvate, Hoeschst
33258, propidium iodide (PI), Triton X-100, DNase-free
RNase A, monodansylcadaverine (MDC), staurosporine
(STS), Wright stain, charcoal and dextran were from
Sigma-Aldrich Co. (Saint Louis, USA). 3H-thymidine was
supplied by Amersham (Amersham International, Amer-
sham, UK). Caspase-GloTM -3/7 luminometric assay was
from Promega Corporation (Madison, WI, USA) and
Annexin V-PE apoptosis detection kit I was from BD Bio-
sciences Pharmingen (San Diego, CA, USA). Liquid scin-
tillation cocktail Universol was purchased from ICN
Radiochemicals (Irvine, CA, USA). Fluorescence-activated
cell sorter (FACS) buffer and FACS Rinse were from Bec-
ton Dickinson (San Jose, CA, USA). Vectashield mounting
medium was from Vector (Burlingame, CA, USA). A
detailed description of the preparation of the steroidsBMC Cell Biology 2008, 9:41 http://www.biomedcentral.com/1471-2121/9/41
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studied in this work is published elsewhere [30]. A stock
solution of 20 mM was prepared in 100% DMSO and
stored as stock solutions at -20°C. Appropriate dilutions
of the compounds were freshly prepared just prior to per-
form the assays.
Preparation of charcoal-stripped fetal bovine serum 
(CFBS)
In order to avoid the interference of the steroids present in
FBS and the estrogenic effects of phenol-red [31], four
days before starting the experiments, MCF-7aro cells
growing in standard MEM medium were changed to E2-
free medium, which consisted of MEM medium without
phenol-red with 5% pre-treated charcoal heat-inactivated
fetal bovine serum (CFBS), 1 mmol/L sodium pyruvate, 2
mmol/L glutamine, 1% penicillin-streptomycin-ampho-
tericin B and 700 ng/ml G418. Steroids were removed by
incubating 500 ml of heat-inactivated FBS with 8 g acti-
vated-charcoal for 24 hr at RT, followed by centrifugation
for 15 min at 4000 g to separate the charcoal from the
serum. The supernatant was sterilized by passage through
a cellulose acetate filter with a 0.22 μm pore size.
Cell culture
The ER-positive aromatase-overexpressing human breast
cancer MCF-7 cell line, MCF-7aro, prepared by stable
transfection with the human placental aromatase gene
and Geneticin selection [32], was kindly provided by Dr.
Shiuan Chen (Beckman Research Institute, City of Hope,
Duarte, CA, U.S.A.). Cells were maintained with Eagles's
minimum essential medium (MEM) with Earle's salts and
1 mmol/L sodium pyruvate, 2 mmol/L glutamine, 1%
penicillin-streptomycin-amphotericin B, 700 ng/ml G418
and 10% heat-inactivated fetal bovine serum in 5% CO2
at 37°C. Culture medium was changed every 3 days. At
80–90% confluence, cells were detached with 0.25%
trypsin/1 mM EDTA during 1 min at room temperature.
Cell morphology was studied by Wright staining.
Thymidine incorporation assay
MCF-7aro cells were seeded in 96-well plates in a medium
containing 5% CFBS and 1 nM testosterone (T) which was
used as aromatase substrate and proliferation inducing
agent. The cells were incubated with different concentra-
tions of compounds 3a and 4a (1–50 μM). As a negative
control, cells were incubated with culture medium plus
DMSO. Incubations were maintained for 1–6 days and
the medium and drugs were refreshed every 3 days. At
each exposure time, 3H-thymidine (0.5 μCi) was added to
each well and incubated at 37°C in 5% CO2 for the last 8
hr. After a cycle of freezing/defrosting, cells were harvested
using a semi-automated cell harvester (Skatron Instru-
ments, Norway), 1 ml scintillation cocktail was added and
3H-thymidine incorporated was determined in a scintilla-
tion counter (LS 6500, Beckman Instruments, CA, USA).
Assays were carried out in triplicate and results are repre-
sentative of at least three independent experiments.
Cell cycle analysis
To investigate the antiproliferative effects of compounds
3a and 4a in MCF-7aro cells, cell cycle analysis was per-
formed by flow cytometry. Cells (7 × 105) were seeded in
T-25 flasks and cultured in medium containing 1 nM T
and with or without inhibitors 3a and 4a, at different con-
centrations (1–50 μM). Untreated cells, incubated with 1
nM T, were considered as control. After 24 hr of treatment,
cells were harvested using 0.25% trypsin and 1 mM EDTA,
mixed with non-adherent cells, washed twice with 5 ml
PBS and resuspended in a final volume of 0.5 ml PBS. The
cell suspension was transferred to 70% cold ethanol and
kept at 4°C for ≥ 2 hr. The ethanol-suspended cells were
centrifuged and the cell pellets washed in PBS. Fixed cells
were finally resuspended in 0.5 ml DNA staining solution
(5 μg/ml PI, 0.1% Triton X-100 and 200 μg/ml DNase-free
RNase A in PBS) and kept 30 min at room temperature.
Flow cytometric analysis of DNA content was based on
the acquisition of 20000 events in a Becton Dickinson
FACSCalibur (San Jose, CA, U.S.A) equipped with CEL-
LQuest Pro software.
Debris, cell doublets and aggregates were gated out using
a two parameter plot of FL-2-Area to FL-2-Width of PI flu-
orescence. Detectors for forward (FSC) and side (SSC)
light scatter and the three fluorescence channels (FL-1, FL-
2 and FL-3) were set on a linear scale. Cell cycle histo-
grams were analysed using FlowJo Software (Tree Star,
Inc). The antiproliferative effect of a compound in this
assay is indicated by the percentage of cells in G0/G1 phase
of the cell cycle. Assays were performed in triplicate.
Analysis of apoptosis
Annexin V-PE apoptosis detection Kit was used, according
to the manufacturer's instructions, to evaluate the apop-
totic cells. Briefly, cells (2 × 105) were cultured in 6-well
plates and treated with or without inhibitors 3a and 4a at
different concentrations (1–25 μM) for 72 h. Adherent
and non-adherent cells after being pooled, washed and
counted were incubated in binding buffer containing
annexinV-PE (5 μl) and 7-ADD (5 μl) for 10 min at RT. As
a positive control, cells were incubated for 12 hr with STS
at 1 μM. Flow cytometric analysis was carried out in a
FACS Calibur (San Jose, CA, U.S.A) based on the acquisi-
tion of 10000 events. Detectors for forward (FSC) and side
(SSC) light scatter were set on a linear scale, whereas log-
arithmic detectors were used for all three fluorescence
channels (FL-1, FL-2 and FL-3). Compensation for spec-
tral overlap between FL channels was performed for each
experiment using single-color-stained cell populations.
All data were collected ungated to disk and were analyzed
using CELLQuest Pro software.BMC Cell Biology 2008, 9:41 http://www.biomedcentral.com/1471-2121/9/41
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Bivariant analysis of Annexin-PE fluorescence (FL-2) and
7AAD-fluorescence (FL-3) distinguished different cell
populations. PE-ve and 7AAD-ve were designated as via-
ble cells; PE+ve and 7AAD-ve were apoptotic cells and
PE+ve and 7AAD+ve were considered as late apoptotic
and necrotic cells.
Hoechst staining was used to evaluate alterations in
nuclear morphology. After treatment for the indicated
times and conditions, cells were washed twice with PBS,
fixed with 4% paraformaldehyde in PBS (pH 7.4) for 10
min at RT, exposed to 0.5 mg/ml Hoechst 33258 in PBS
for 20 min at room temperature and mounted in vectash-
ield. The nuclear morphology was examined under a flu-
orescence microscope (Eclipse E400, Nikon, Japan),
equipped with an excitation filter with maximum trans-
mission at 360/400 nm, and processed by Nikon ACT-2U
image software.
Caspase-3/7 activity was also evaluated using the Caspase-
GloTM -3/7 luminometric assay, after incubation of MCF-
7aro cells with the compounds for different incubation
periods (6–96 hr).
Analysis of intracellular vacuoles
MCF-7aro cells were seeded in 8-chamber wells and
treated with compounds 3a and 4a (25 μM) for 72 hr.
Fresh MEM containing 25 μM MDC was added to the cells
and incubated at 37°C for 1 hr. After washing with PBS
and mounting with vectashield medium, cells were imme-
diately analysed in a fluorescence microscope (Axioskop,
Carl Zeiss, Germany) equipped with a CCD Spot 2 camera
(Diagnostic Instruments, USA) and image software Spot
3.1 (Diagnostic Instruments, USA). Images were obtained
with a filter set 40 (Carl Zeiss, Germany) with excitation
BP 360/51, beam splitter TFT 440+500+570 and emission
filter TBP 460+520+600.
For electron microscopy, cells were harvested by tripsini-
zation after 72 hr incubation with the compounds (25
μM), washed with sodium cacodilate (50 mM, pH 7.4),
fixed with 1.25% glutaraldehyde/4% paraformaldehyde
and preserved at 4°C for further processing. The cells were
post-fixed in 1% osmium tetroxide in the same buffer,
dehydrated in graded alcohols and embebed in Epon 812.
Ultra-thin sections obtained with a Reichert Supra Nova
ultramicrotome were collected on copper grids, stained
with uranyl acetate/lead citrate and examined in a Zeiss
902A transmission electron microscope.
Statistical analysis
The data presented are expressed as the mean ± SE. Statis-
tical analysis of data was performed using analysis of var-
iance (ANOVA) followed by Bonferroni post-hoc test for
multiple comparisons. Values of P < 0.05 were considered
as statistically significant.
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